mitomycin has been researched along with Diarrhea in 23 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 9.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 9.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| "No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy." | 9.08 | Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995) |
| "We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 9.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 7.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| "Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment of anal cancer." | 5.17 | Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ( Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Dewit, L; Schellens, JH, 2013) |
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 5.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 5.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| "No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy." | 5.08 | Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995) |
| "We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 5.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
| "Accurate description of current practice within advanced colorectal cancer (CRC) specialties were needed to inform an economic evaluation of the UGT1A1 pharmacogenetic test for irinotecan in the United Kingdom." | 3.76 | Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. ( Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW, 2010) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 3.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| " We screened cancer patients' tumors for FA functional defects then aimed to establish the safety/feasibility of administering PARP inhibitors as monotherapy and combined with a DNA-breaking agent." | 2.82 | Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. ( Bekaii-Saab, T; Chen, A; Duan, W; Ji, J; Lustberg, M; Marshall, J; Rose, J; Schaaf, LJ; Shilo, K; Thurmond, J; Timmers, C; Villalona-Calero, MA; Westman, JA; Xiaobai, L; Zhao, W, 2016) |
| " Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0." | 2.75 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010) |
| " In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))." | 2.73 | Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007) |
| "169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B)." | 2.72 | Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. ( Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N, 2006) |
| "Twenty-one stomach cancer patients and 34 colorectal cancer patients were registered in the study." | 2.67 | [Study of 5'-DFUR treatment as postoperative adjuvant chemotherapy for stomach and colorectal cancer. Tokai GATS Group (pilot study)]. ( Hachisuka, K; Honda, H; Honda, K; Maeda, A; Nakazato, H; Tsuruga, N; Yamaguchi, A; Yoshizaki, S; Yura, J, 1994) |
| " Patient acute gastrointestinal toxicity was recorded using Common Terminology Criteria of Adverse Events (CTCAE) diarrhoea grading." | 1.48 | Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes. ( Amor, H; Blakey, D; Chao, M; Guerrieri, M; Guiney, M; Ho, H; Macleod, C; Melven, L; Ng, M; Skelton, J; Subramanian, B, 2018) |
| "Grade 3-4 neutropenia was seen in 10/23 patients (43%)." | 1.46 | PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. ( Beer, J; Bodis, S; Oehler, C; Vlachopoulou, V; von Moos, R; Zimmermann, M; Zwahlen, DR, 2017) |
| "Mitomycin C suppository was significantly less toxic compared with intravenous delivery, and higher rectal tissue concentrations were observed from 10 to 30 minutes (P < 0." | 1.30 | Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer. ( Ackerman, D; Galandiuk, S; Hofmeister, A; LaRocca, R; Lewis, RK; Myers, SR; Paris, KJ; Pokorny, RM; Wrightson, WR, 1997) |
| " Pharmacokinetic examination after intravenous injection of low-dose MMC (0." | 1.29 | A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics. ( Boku, N; Ishii, H; Kaneko, K; Kusada, O; Muro, K; Muto, M; Ohkuwa, M; Ohtsu, A; Sasaki, Y; Tajiri, H; Yoshida, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 7 (30.43) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Lukovic, J | 3 |
| Hosni, A | 3 |
| Liu, A | 3 |
| Chen, J | 3 |
| Tadic, T | 3 |
| Patel, T | 3 |
| Li, K | 3 |
| Han, K | 3 |
| Lindsay, P | 3 |
| Craig, T | 3 |
| Brierley, J | 3 |
| Barry, A | 3 |
| Wong, R | 3 |
| Ringash, J | 3 |
| Dawson, LA | 3 |
| Kim, JJ | 3 |
| Zimmermann, M | 1 |
| Beer, J | 1 |
| Bodis, S | 1 |
| von Moos, R | 1 |
| Vlachopoulou, V | 1 |
| Zwahlen, DR | 1 |
| Oehler, C | 1 |
| Ng, M | 1 |
| Ho, H | 1 |
| Skelton, J | 1 |
| Guerrieri, M | 1 |
| Guiney, M | 1 |
| Chao, M | 1 |
| Blakey, D | 1 |
| Macleod, C | 1 |
| Amor, H | 1 |
| Subramanian, B | 1 |
| Melven, L | 1 |
| Deenen, MJ | 1 |
| Dewit, L | 1 |
| Boot, H | 1 |
| Beijnen, JH | 1 |
| Schellens, JH | 1 |
| Cats, A | 1 |
| Villalona-Calero, MA | 1 |
| Duan, W | 1 |
| Zhao, W | 1 |
| Shilo, K | 1 |
| Schaaf, LJ | 1 |
| Thurmond, J | 1 |
| Westman, JA | 1 |
| Marshall, J | 1 |
| Xiaobai, L | 1 |
| Ji, J | 1 |
| Rose, J | 1 |
| Lustberg, M | 1 |
| Bekaii-Saab, T | 1 |
| Chen, A | 1 |
| Timmers, C | 1 |
| Kruth, J | 1 |
| Nissen, J | 1 |
| Ernst, T | 2 |
| Kripp, M | 2 |
| Lukan, N | 2 |
| Merx, K | 2 |
| Hofmann, WK | 1 |
| Hochhaus, A | 2 |
| Hofheinz, RD | 2 |
| Tebbutt, NC | 1 |
| Wilson, K | 1 |
| Gebski, VJ | 1 |
| Cummins, MM | 1 |
| Zannino, D | 1 |
| van Hazel, GA | 1 |
| Robinson, B | 1 |
| Broad, A | 1 |
| Ganju, V | 1 |
| Ackland, SP | 1 |
| Forgeson, G | 1 |
| Cunningham, D | 1 |
| Saunders, MP | 1 |
| Stockler, MR | 1 |
| Chua, Y | 1 |
| Zalcberg, JR | 1 |
| Simes, RJ | 1 |
| Price, TJ | 1 |
| Shabaruddin, FH | 1 |
| Elliott, RA | 1 |
| Valle, JW | 1 |
| Newman, WG | 1 |
| Payne, K | 1 |
| Di Bartolomeo, M | 1 |
| Buzzoni, R | 1 |
| Mariani, L | 1 |
| Ferrario, E | 1 |
| Katia, D | 1 |
| Gevorgyan, A | 1 |
| Zilembo, N | 1 |
| Bordonaro, R | 1 |
| Bochicchio, AM | 1 |
| Massidda, B | 1 |
| Ardizzoia, A | 1 |
| Ardizzoni, A | 1 |
| Marini, G | 1 |
| Aitini, E | 1 |
| Schieppati, G | 1 |
| Comella, G | 1 |
| Pinotti, G | 1 |
| Palazzo, S | 1 |
| Cicero, G | 1 |
| Bajetta, E | 1 |
| Villa, E | 1 |
| Fagnani, D | 1 |
| Reguzzoni, G | 1 |
| Agostana, B | 1 |
| Oliani, C | 1 |
| Kildani, B | 1 |
| Duro, M | 1 |
| Botta, M | 1 |
| Mozzana, R | 1 |
| Mantovani, G | 1 |
| Gnad-Vogt, U | 1 |
| Schultheis, B | 1 |
| Glynne-Jones, R | 1 |
| Meadows, H | 1 |
| Wan, S | 1 |
| Gollins, S | 1 |
| Leslie, M | 1 |
| Levine, E | 1 |
| McDonald, AC | 1 |
| Myint, S | 1 |
| Samuel, L | 1 |
| Sebag-Montefiore, D | 1 |
| Inokuchi, K | 1 |
| Hattori, T | 1 |
| Taguchi, T | 1 |
| Abe, O | 1 |
| Ogawa, N | 1 |
| Nakata, E | 1 |
| Okajima, K | 1 |
| Ishida, Y | 1 |
| Munetomo, Y | 1 |
| Gotoh, K | 1 |
| Toyohara, M | 1 |
| Miyazaki, H | 1 |
| Matsunaga, S | 1 |
| Maeura, Y | 1 |
| Fujimura, T | 1 |
| Francini, G | 1 |
| Petrioli, R | 1 |
| Aquino, A | 1 |
| Gonnelli, S | 1 |
| Conti, JA | 1 |
| Kemeny, NE | 1 |
| Saltz, LB | 1 |
| André, AM | 1 |
| Grossano, DD | 1 |
| Bertino, JR | 1 |
| Yamaguchi, A | 1 |
| Maeda, A | 1 |
| Hachisuka, K | 1 |
| Yura, J | 1 |
| Honda, K | 1 |
| Honda, H | 1 |
| Yoshizaki, S | 1 |
| Tsuruga, N | 1 |
| Nakazato, H | 1 |
| Boku, N | 1 |
| Ohtsu, A | 1 |
| Muro, K | 2 |
| Kaneko, K | 1 |
| Muto, M | 1 |
| Ohkuwa, M | 1 |
| Ishii, H | 1 |
| Sasaki, Y | 1 |
| Tajiri, H | 1 |
| Yoshida, S | 1 |
| Kusada, O | 1 |
| Pokorny, RM | 1 |
| Wrightson, WR | 1 |
| Lewis, RK | 1 |
| Paris, KJ | 1 |
| Hofmeister, A | 1 |
| LaRocca, R | 1 |
| Myers, SR | 1 |
| Ackerman, D | 1 |
| Galandiuk, S | 1 |
| Hartmann, JT | 1 |
| Harstrick, A | 1 |
| Daikeler, T | 1 |
| Kollmannsberger, C | 1 |
| Müller, C | 1 |
| Seeber, S | 1 |
| Kanz, L | 1 |
| Bokemeyer, C | 1 |
| Sobrero, A | 1 |
| Guglielmi, A | 1 |
| Cirillo, M | 1 |
| Recaldin, E | 1 |
| Frassineti, GL | 1 |
| Aschele, C | 1 |
| Ravaioli, A | 1 |
| Testore, P | 1 |
| Caroti, C | 1 |
| Gallo, L | 1 |
| Pessi, MA | 1 |
| Cortesi, E | 1 |
| Turci, D | 1 |
| Grossi, F | 1 |
| Labianca, R | 1 |
| Valentini, V | 1 |
| Coco, C | 1 |
| Cellini, N | 1 |
| Picciocchi, A | 1 |
| Fares, MC | 1 |
| Rosetto, ME | 1 |
| Mantini, G | 1 |
| Morganti, AG | 1 |
| Barbaro, B | 1 |
| Cogliandolo, S | 1 |
| Nuzzo, G | 1 |
| Tedesco, M | 1 |
| Ambesi-Impiombato, F | 1 |
| Cosimelli, M | 1 |
| Rotman, M | 1 |
| Yamao, T | 1 |
| Shirao, K | 1 |
| Matsumura, Y | 1 |
| Yamada, Y | 1 |
| Goto, M | 1 |
| Chin, K | 1 |
| Shimada, Y | 1 |
| Becouarn, Y | 1 |
| Calabet, J | 1 |
| Brunet, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250] | Phase 2 | 264 participants (Actual) | Interventional | 2019-11-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 trials available for mitomycin and Diarrhea
| Article | Year |
|---|---|
Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 2013 |
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; | 2016 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Ne | 2010 |
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2006 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2008 |
Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Moda | 1984 |
[Combination therapy of high dose 5'-DFUR+MMC for advanced or recurrent gastric cancer. 5'-DFUR Joint Research Group in the Osaka District for Gastric Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule; | 1995 |
Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1995 |
[Study of 5'-DFUR treatment as postoperative adjuvant chemotherapy for stomach and colorectal cancer. Tokai GATS Group (pilot study)].
Topics: Administration, Oral; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; | 1994 |
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Colorectal Neoplasms; Diarrhea; Disease Progressio | 1998 |
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Conjunctivitis; D | 2001 |
Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined | 2001 |
Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response R | 2001 |
8 other studies available for mitomycin and Diarrhea
| Article | Year |
|---|---|
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2017 |
Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Topics: Abdominal Cavity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; An | 2018 |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; | 2010 |
Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug Evalua | 1993 |
A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Diseas | 1996 |
Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer.
Topics: Adenocarcinoma; Administration, Rectal; Animals; Antibiotics, Antineoplastic; Chromatography, High P | 1997 |
Phase II study of a 5-fluorouracil, teniposide and mitomycin-C combination chemotherapy in advanced colorectal carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Colonic Neoplasms; Diarrhea; D | 1988 |